Edgewise Therapeutics

Wishing you a healthy and festive holiday season from the Edgewise team!

Add muscle to your career! We're looking to fill for 4 new positions on our dynamic team: ▪︎ Director, Head of Statistical Programming ▪︎ Director/Senior Director, Medical Affairs - Cardiovascular ▪︎ Senior Manager, Clinical Quality Assurance ▪︎ Senior Manager/Associate Director, QA Operations Edgewise Therapeutics is committed to improving the lives of individuals living with serious musculoskeletal and cardiac diseases. Our dedicated research focuses on the development of life-changing therapeutics for people in need. Be part of something bigger. Apply today: https://lnkd.in/eG_pgJbU #Edgewise #NowHiring

Exciting, collaborative, and rewarding– the three words Emily Bonnabeau, Manager, Clinical Operations, with our skeletal muscle clinical team used to describe working at Edgewise Therapeutics. Hear what Emily finds the most rewarding about her role and the work we’re doing behind-the-scenes: “Managing clinical trials offers a valuable opportunity to drive meaningful change for the communities we serve. I feel fortunate to work with a supportive team, united by a shared goal to help bring novel therapies to the Duchenne and Becker community.” #TeamSpotlight #EdgewiseTherapeutics #CompanyCulture

Today we announced positive top-line data from the Phase 2 CANYON trial in individuals with Becker muscular dystrophy. See our press release to learn more: https://lnkd.in/ed_9rQq3

Hypertrophic Cardiomyopathy (HCM) is the most common form of genetic heart disease. Chronic and progressive in nature, individuals affected may experience an increased risk of heart failure, stroke, and atrial fibrillation. Learn more about HCM, including subtypes, characterizations, and common symptoms associated with the disease at https://lnkd.in/dnrtt353 #HCMAwareness #HCM #HypertrophicCardiomyopathy

Consider a clinical trial in Becker muscular dystrophy (BMD). beckergcstudy.com - Considere la posibilidad de participar en un ensayo clínico sobre la distrofia muscular de Becker (BMD).

Meet Alan Russell, our Co-Founder and Chief Scientific Officer! Alan's expertise is in muscle biology and has dedicated his 20+ year career to advancing new treatments for serious muscle diseases. Alan earned his BPharm and PhD from the University of Bath in the UK, and completed his Postdoctoral training at the Stanford University School of Medicine. Over the summer, Alan enjoyed volunteering his time with kids living with Duchenne at the Jett Foundation's summer camp, where he got to be a judge for the Shark Tank activity! Read this and more in our latest quarterly patient community newsletter: https://lnkd.in/ekRq5kC2 #Becker #Duchenne #MuscularDystrophy

We’ll be attending the CVCT Cardiovascular Clinical Trialists Forum! Join us at the scientific poster session where we will continue to share topline data from our EDG-7500 Phase 1 trial in healthy adults and CIRRUS-HCM Phase 2 trial in patients with oHCM and two panel discussions with Marc Semigran, MD, our Chief Development Officer, on Dec 10. Panel topics include HCM detection, clinical management, and future trial challenges. #CVCT2024 #HCM

Building a strong community of patients, caregivers and health professionals is often the key to turning the tide for people living with a rare disease. A shining example of this is currently underway in Becker muscular dystrophy. Read here: https://lnkd.in/g3yNfcyU Edgewise Therapeutics

Attention Becker community: watch our new NSAA video! Learn how the NSAA, or North Star Ambulatory Assessment, is used in clinical research and medical care, and what it means for YOU. Watch the video here: https://lnkd.in/dmupaacP #Becker #MuscularDystrophy